Morgan Stanley
MS
$206.58
-3.64%
Morgan Stanley is a global financial services holding company operating across three core segments: Institutional Securities (investment banking, sales & trading, and prime brokerage), Wealth Management (the firm's largest earnings engine, with roughly $9.3 trillion in client assets), and Investment Management. With offices in 42 countries and approximately 83,000 employees, the firm is one of the two preeminent bulge-bracket franchises alongside Goldman Sachs, but its distinguishing feature is the scale and stability of its wealth management platform, which now generates the majority of firmwide income and has transformed MS from a trading-dependent risk-taker into a more fee-based, capital-light earnings compounder. The current investor narrative centers on whether that transformation can sustain record profitability through a capital-markets upcycle: Q2 2026 revenue of $34.47 billion grew 22.4% year over year, EPS of $3.46 rose sharply versus $2.15 a year earlier, and the stock has rallied roughly 37% over the past twelve months as M&A and underwriting activity rebounded. At the same time, a July downgrade wave arguing that large-cap bank stocks are 'priced for perfection' ahead of Q2 earnings, plus a mixed institutional rating backdrop (Oppenheimer downgraded to Underperform on June 30), frames the central debate: is MS's premium multiple justified by structurally higher wealth-management earnings power, or has the market already discounted the cyclical recovery?…
MS
Morgan Stanley
$206.58
Related headlines
Investment Opinion: Should I buy MS Today?
Rating: Buy. Morgan Stanley offers a compelling blend of cyclical recovery and structural growth, with a forward PE of 15.71x and a PEG of 0.60 that suggest the stock is undervalued relative to its earnings growth. The analyst consensus rating is 'buy' with an average target of $237.33, implying 10.7% upside, and the firm's wealth management platform provides a durable fee-based earnings stream that supports a premium multiple.
The supporting evidence is strong: Q2 2026 revenue grew 22.4% year over year to $34.47 billion, EPS jumped 61% to $3.46, and the net margin improved to 16.19% from 12.57% a year earlier. The dividend yield of 2.36% and payout ratio of 39.1% indicate a sustainable capital return policy, while the 20.78% relative outperformance versus the SPY over the past year demonstrates market confidence. The forward PE of 15.71x is below the trailing PE of 17.17x, reflecting expected earnings growth, and the PEG ratio of 0.60 is attractive compared to the broader financial sector.
However, risks include negative free cash flow of -$1.052 billion, a high debt-to-equity ratio of 4.26, and the potential for valuation compression if capital markets activity slows. The rating would upgrade to Strong Buy if free cash flow turns positive and the forward PE remains below 16x, or downgrade to Hold if revenue growth decelerates below 10% or if the stock breaks below its 52-week low of $151.84. Relative to its history and peers, MS appears fairly valued to slightly undervalued, with the market pricing in mid-teens earnings growth that the firm is currently exceeding.
Sign up to view all
MS 12-Month Price Forecast
Morgan Stanley is well-positioned to benefit from the ongoing capital-markets recovery, with strong revenue and EPS growth, an attractive forward valuation, and a durable wealth management franchise. The analyst consensus is bullish, and the stock has significant upside to the average target. However, risks include negative free cash flow, high leverage, and the potential for valuation compression if growth slows. I would upgrade to high confidence if free cash flow turns positive and the stock breaks above $230, or downgrade to neutral if revenue growth falls below 10% or if the stock breaks below $200.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $237.33 and implied upside of +14.9% versus the current price.
Average Target
$237.33
0 analysts
Implied Upside
+14.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$184 - $262
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: MS Investment Factors
The bull case for Morgan Stanley rests on its successful transformation into a wealth-management-led franchise, with $9.3 trillion in client assets generating recurring fee income, and a sharp cyclical recovery in capital markets driving 22.4% revenue growth and 61% EPS growth in Q2 2026. The stock trades at a forward PE of 15.71x with a PEG of 0.60, and analysts see 10.7% upside to their average target of $237.33. However, the bear case is gaining traction: a July downgrade wave argues bank stocks are 'priced for perfection,' Oppenheimer downgraded MS to Underperform, and the stock has underperformed the SPY over the past three months. The most important tension is whether the wealth management platform can sustain record profitability through a full capital-markets cycle, or whether the market has already discounted the cyclical recovery. Currently, the bull evidence is stronger due to accelerating earnings and attractive forward valuation, but the bear case cannot be dismissed given negative free cash flow and premium valuation concerns.
Bullish
- Wealth management drives fee-based earnings: Morgan Stanley's wealth and asset management franchises generated the majority of firmwide income in 2025, with $9.3 trillion in client assets and over $400 billion in customer deposits. This capital-light, recurring fee stream reduces reliance on volatile trading revenue and supports a structurally higher earnings multiple than pure investment banks.
- Revenue and EPS accelerating sharply: Q2 2026 revenue of $34.47 billion grew 22.4% year over year, while EPS of $3.46 rose 61% versus $2.15 in Q2 2025. This acceleration reflects a rebound in M&A and underwriting activity, and the trailing twelve-month EPS trajectory has moved from $2.15 to $3.46 in just four quarters.
- Analyst consensus sees 10.7% upside: With 21 analysts covering the stock, the average price target is $237.33 versus the current price of $214.38, implying roughly 10.7% upside. The high target of $262 suggests 22.2% upside if the capital-markets upcycle exceeds expectations.
- Attractive forward valuation: The forward PE of 15.71x is below the trailing PE of 17.17x, indicating expected earnings growth. The PEG ratio of 0.60 is well below 1.0, suggesting the stock is undervalued relative to its earnings growth rate, and the dividend yield of 2.36% provides income support.
Bearish
- Premium valuation vulnerable to downgrades: A July 2026 downgrade wave argued that large-cap bank stocks are 'priced for perfection' ahead of Q2 earnings, with analysts recommending rotation into super-regional banks. Oppenheimer downgraded MS to Underperform on June 30, 2026, citing valuation concerns after the stock's 37% one-year rally.
- Negative free cash flow raises questions: Despite record revenue, MS reported negative free cash flow of -$1.052 billion on a trailing twelve-month basis. This cash burn, if sustained, could limit the firm's ability to fund buybacks or dividends without increasing debt, especially with a debt-to-equity ratio of 4.26.
- High leverage amplifies downside risk: The debt-to-equity ratio of 4.26 is elevated, typical for a bank holding company but still a risk if credit conditions deteriorate. A 19.28% maximum drawdown over the past year shows the stock is not immune to sharp corrections, and the beta of 1.207 means it amplifies market moves.
- Momentum has stalled recently: Over the past month, MS declined 1.50% while the SPY fell only 1.06%, resulting in a relative strength of -0.44%. Over three months, the stock underperformed the SPY by 2.88 percentage points, suggesting the near-term rally may be losing steam.
MS Technical Analysis
Beta
1.21
1.21x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$152-$232
Price range past year
Annual Return
+32.1%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | -5.0% | -2.0% |
| 3m | -6.5% | +1.4% |
| 6m | +30.0% | +15.0% |
| 1y | +32.1% | +15.7% |
| ytd | +13.6% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Quarterly Revenue
$34.5B
2026-06
Revenue YoY Growth
+22.4%
YoY Comparison
Gross Margin
61.7%
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
PE
17.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Morgan Stanley's financial risks are primarily tied to its leverage and cash flow profile. The debt-to-equity ratio of 4.26 is high, though typical for a bank holding company, and the firm reported negative free cash flow of -$1.052 billion on a trailing twelve-month basis, which could constrain capital returns if sustained. Additionally, the payout ratio of 39.1% and dividend yield of 2.36% mean that any earnings decline could pressure the dividend, especially given the cyclical nature of investment banking revenue. The current ratio of 1.17 is adequate but not strong, leaving little buffer if liquidity conditions tighten.
Market and competitive risks are significant given the stock's 37% one-year rally and premium valuation. The forward PE of 15.71x may appear reasonable, but the July 2026 downgrade wave and Oppenheimer's Underperform rating highlight concerns that the stock is 'priced for perfection.' With a beta of 1.207, MS is more volatile than the broader market, and any macro slowdown or regulatory headwind could trigger multiple compression. Competition from super-regional banks and alternative asset managers, as noted in recent news, could also pressure market share in wealth management and investment banking.
The worst-case scenario would involve a sharp reversal in capital markets activity, a deterioration in credit quality, and a regulatory crackdown on bank capital requirements. In such a scenario, MS could retest its 52-week low of $151.84, representing a 29.2% decline from the current price of $214.38. The analyst low target of $184 implies a 14.2% downside, but a more severe downturn could push the stock below $150, especially if negative free cash flow persists and the firm is forced to cut its dividend or raise equity. Investors should be prepared for a potential drawdown of 20-30% in a bear case.
FAQ
The key risks include: 1) Financial risk: negative free cash flow of -$1.052 billion and a high debt-to-equity ratio of 4.26 could limit capital returns. 2) Market risk: a beta of 1.207 means the stock is more volatile than the market, and a 19.28% max drawdown shows vulnerability to sharp corrections. 3) Competitive risk: downgrades from Oppenheimer and others suggest the stock is 'priced for perfection,' and competition from super-regional banks could pressure market share. 4) Macro risk: a slowdown in M&A and trading activity would directly impact revenue, as seen in the cyclical nature of investment banking. These risks are ranked from most to least severe, with financial and market risks being the most immediate.
The 12-month forecast has three scenarios: bull case (25% probability) with a target range of $250-$262, driven by an accelerating capital-markets upcycle and EPS above $17; base case (55% probability) with a target range of $230-$245, assuming moderate growth and EPS of $16.34; and bear case (20% probability) with a target range of $184-$200, reflecting a slowdown and multiple compression. The base case is most likely, with the key assumption that revenue growth moderates to 10-15% and the forward PE remains in the 15-16x range. The analyst average target of $237.33 aligns with the base case.
MS appears fairly valued to slightly undervalued. The forward PE of 15.71x is below the trailing PE of 17.17x, indicating expected earnings growth, and the PEG ratio of 0.60 is well below 1.0, suggesting undervaluation relative to growth. The price-to-book ratio of 2.50 is in line with peers like Goldman Sachs, and the dividend yield of 2.36% is above the sector average. The market is pricing in mid-teens earnings growth, which the firm is currently exceeding with 22.4% revenue growth. If growth slows, the multiple could compress, but at current levels, the stock offers a reasonable entry point.
From a risk/reward perspective, MS appears attractive for investors with a medium-term horizon. The stock trades at a forward PE of 15.71x with a PEG of 0.60, and analysts see 10.7% upside to their average target of $237.33. The biggest downside risk is a capital-markets slowdown that could push the stock to its 52-week low of $151.84, representing a 29% decline. However, the wealth management platform provides a cushion, and the dividend yield of 2.36% offers income. It is a good buy for those who believe the capital-markets recovery will continue and can tolerate a beta of 1.207.
MS is suitable for both, but it is better suited for medium-to-long-term investors. The stock has a beta of 1.207, indicating higher volatility than the market, which makes it less ideal for short-term trading unless one can actively manage risk. The dividend yield of 2.36% and payout ratio of 39.1% provide income, and the wealth management platform offers long-term growth potential. Earnings visibility is moderate, with analyst estimates for EPS of $16.34 in the next year. A suggested minimum holding period is 12-18 months to ride out cyclical fluctuations and benefit from the capital-markets recovery.
